Skip to content

Inflammation in facioscapulohumeral muscular dystrophy

Inflammation in facioscapulohumeral muscular dystrophy - Inflammation in FSHD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43090
Enrollment
10
Registered
2016-08-01
Start date
2017-07-20
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscular dystrophy

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -18-65 year old -Genetically confirmed FSHD1

Exclusion criteria

Exclusion criteria: -Age 65 years old -Diabetes mellitus -Chronic obstructive pulmonary disease -Current malignancy -Previous treatment with chemotherapy and/or radiation therapy -Use of corticosteroids during more than two weeks in the past 5 years -Use of statins in the past year

Design outcomes

Primary

MeasureTime frame
We expect to better understand if and which role inflammation plays in the disease pathogenesis by evaluating the following outcomes: percentage and features of PBMC, cytokine profiling and autoantibodies inquiry both in FSHD1 patients and in healthy controls. Moreover, disease severity of FSHD patients will be assessed using a clinical severity score (Ricci-score).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)